IBR900

Phase Ia main study objectives 1) To evaluate the safety and tolerability of the study drug in subjects with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma. 2) To determine the recommended Phase II dose for subjects with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma to receive the study drug. Phase Ia secondary study objectives 1) To preliminarily evaluate the efficacy of the study drug in subjects with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma. 2) Pharmacokinetic (PK) characteristics of IBR900 cell injection in subjects with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma.